LDLR and familial hypercholesterolemia: Taken together, RiPSCs have great promise in cardiac repair [58,63,68] and a new drug discovery [61,64], especially genetic correction of specific defects such as β-thalassemia [62,88,89] and low-density lipoprotein receptor (LDLR) deficiency familial hypercholesterolemia [64].